Surgery Partners Q4 2021 Adj. EBITDA $114.4M, raises 2022 guidance

Surgery Partners, Inc.

2021-FY EPS reported -$1.12 revenue$2,225,100,000

Q4 2021 revenue $610.2M (+11.3% YoY); net loss $0.1M; Adj. EBITDA $114.4M (+26.0%, incl. $11.6M CARES grants).
Full-year 2021 revenue $2.225B (+19.6% YoY); Adj. EBITDA $339.6M (+32.3%, incl. $25.3M CARES grants).
Days adjusted same-facility revenue +9.6% in Q4; case volume +4.2%. Full-year same-facility revenue +18.1%.
2022 guidance: revenue at least $2.5B (+12% YoY); Adj. EBITDA $370-380M, raised from prior outlook.
Cash $389.9M at Dec. 31; total net debt/EBITDA leverage 5.58x; capital deployment target at least $200M annually.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.